GlassScriptPhysician profile
David A Martin
NPI 1639131022
$2,570.95
in general payments reported to CMS, 2019-2025
31 companies · $992 in 2025
The $992 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $125 · 2021: $288 · 2022: $13.60 · 2023: $181 · 2024: $736 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,908.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $559.91 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $215.97 | 2019-2021 | |
| Novo Nordisk INC | $174.81 | 2021-2025 | Wegovy, Ozempic |
| Abbott Laboratories | $147.92 | 2024-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $145.00 | 2019 | |
| Abbvie INC. | $141.70 | 2024-2025 | |
| Allergan, INC. | $125.00 | 2020 | |
| Boston Scientific Corporation | $100.00 | 2021 | |
| Phathom Pharmaceuticals, INC. | $97.88 | 2024-2025 | Voquezna |
| Pfizer INC. | $93.38 | 2025 | |
| Amgen INC. | $87.21 | 2024-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $81.76 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Astellas Pharma US INC | $80.14 | 2023-2025 | Veozah |
| Glaxosmithkline, LLC. | $74.76 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.61 | 2025 | Caplyta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $63.14 | 2024-2025 | Ibsrela |
| Xeris Pharmaceuticals, INC. | $37.27 | 2025 | Gvoke Hypopen |
| Radius Health, INC. | $34.45 | 2025 | Tymlos |
| Exact Sciences Corporation | $33.28 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $31.85 | 2024-2025 | Entyvio, Trintellix |
| Irhythm Technologies, INC. | $22.87 | 2024 | Zio Monitor, Zio Xt Patch |
| Forte Bio-Pharma LLC | $19.44 | 2024 | Prolate, Nalocet |
| E.R. Squibb & Sons, L.L.C. | $19.20 | 2025 | Eliquis |
| Sumitomo Pharma America, INC. | $16.77 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $16.37 | 2025 | Proquad, Vaxelis, Vaxneuvance |
| Insulet Corporation | $15.77 | 2025 | Omnipod |
| Viatris Specialty LLC | $14.77 | 2025 | Yupelri |
| Ironwood Pharmaceuticals, INC | $14.68 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.26 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $13.60 | 2022 | |
| Intra-Sana Laboratories | $13.18 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.